tirzepatide discontinued FDA reconsidering its decision to take off its drug shortage list Does discontinuing tirzepatide lead to

This July meeting is the first formal step toward potentially reversing that position for seven of those 19 compounds

A., & Mbah, J

Typical controlled evaluations may include visual inspection, temperature stability, analytical verification, compatibility assessment and documentation of handling characteristics

Endogenous toxins include the metabolic byproducts of our own cellular respiration, such as reactive oxygen species (ROS) and free radicals

Direct answer: FDA first removed tirzepatide from shortage status in 2024, then confirmed the shortage was resolved in December 2024, then allowed limited wind-down periods that ended in 2025